These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1180 related items for PubMed ID: 9819447

  • 1. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group.
    Davis GL, Esteban-Mur R, Rustgi V, Hoefs J, Gordon SC, Trepo C, Shiffman ML, Zeuzem S, Craxi A, Ling MH, Albrecht J.
    N Engl J Med; 1998 Nov 19; 339(21):1493-9. PubMed ID: 9819447
    [Abstract] [Full Text] [Related]

  • 2. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group.
    McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, Ling MH, Cort S, Albrecht JK.
    N Engl J Med; 1998 Nov 19; 339(21):1485-92. PubMed ID: 9819446
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Combination treatment with interferon alfa-2b and ribavirin for chronic hepatitis C in patients who have failed to achieve sustained response to interferon alone: Swedish experience.
    Schvarcz R, Ando Y, Sönnerborg A, Weiland O.
    J Hepatol; 1995 Nov 19; 23 Suppl 2():17-21. PubMed ID: 8720289
    [Abstract] [Full Text] [Related]

  • 8. Combination antiviral therapy with ribavirin and interferon alfa in interferon alfa relapsers and non-responders: Italian experience.
    Brillanti S, Miglioli M, Barbara L.
    J Hepatol; 1995 Nov 19; 23 Suppl 2():13-5; discussion 15-6. PubMed ID: 8720288
    [Abstract] [Full Text] [Related]

  • 9. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection.
    McHutchison JG, Lawitz EJ, Shiffman ML, Muir AJ, Galler GW, McCone J, Nyberg LM, Lee WM, Ghalib RH, Schiff ER, Galati JS, Bacon BR, Davis MN, Mukhopadhyay P, Koury K, Noviello S, Pedicone LD, Brass CA, Albrecht JK, Sulkowski MS, IDEAL Study Team.
    N Engl J Med; 2009 Aug 06; 361(6):580-93. PubMed ID: 19625712
    [Abstract] [Full Text] [Related]

  • 10. Treatment of genotype 1b HCV-related chronic hepatitis: efficacy and toxicity of three different interferon alfa-2b/ribavirin combined regimens in naive patients.
    Scotto G, Fazio V, Palumbo E, Cibelli DC, Saracino A, Angarano G.
    New Microbiol; 2005 Jan 06; 28(1):23-9. PubMed ID: 15782623
    [Abstract] [Full Text] [Related]

  • 11. Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin.
    Bronowicki JP, Ouzan D, Asselah T, Desmorat H, Zarski JP, Foucher J, Bourlière M, Renou C, Tran A, Melin P, Hézode C, Chevalier M, Bouvier-Alias M, Chevaliez S, Montestruc F, Lonjon-Domanec I, Pawlotsky JM.
    Gastroenterology; 2006 Oct 06; 131(4):1040-8. PubMed ID: 17030174
    [Abstract] [Full Text] [Related]

  • 12. Interferon alfa-2b in combination with ribavirin for the treatment of chronic hepatitis C in children: efficacy, safety, and pharmacokinetics.
    González-Peralta RP, Kelly DA, Haber B, Molleston J, Murray KF, Jonas MM, Shelton M, Mieli-Vergani G, Lurie Y, Martin S, Lang T, Baczkowski A, Geffner M, Gupta S, Laughlin M, International Pediatric Hepatitis C Therapy Group.
    Hepatology; 2005 Nov 06; 42(5):1010-8. PubMed ID: 16250032
    [Abstract] [Full Text] [Related]

  • 13. Safety of combination interferon alfa-2b/ribavirin therapy in chronic hepatitis C-relapsed and treatment-naive patients.
    Maddrey WC.
    Semin Liver Dis; 1999 Nov 06; 19 Suppl 1():67-75. PubMed ID: 10349694
    [Abstract] [Full Text] [Related]

  • 14. Retreatment for 24 vs 48 weeks with interferon-alpha2b plus ribavirin of chronic hepatitis C patients who relapsed or did not respond to interferon alone.
    Enríquez J, Gallego A, Torras X, Pérez-Olmeda T, Diago M, Soriano V, Luján MS, García-Samaniego J.
    J Viral Hepat; 2000 Nov 06; 7(6):403-8. PubMed ID: 11115050
    [Abstract] [Full Text] [Related]

  • 15. Daily or three times a week interferon alfa-2b in combination with ribavirin or interferon alone for the treatment of patients with chronic hepatitis C.
    de Lédinghen V, Trimoulet P, Winnock M, Foucher J, Bourlière M, Desmorat H, Canva V, Capron D, Lévy S, Mion F, Mannant PR, Chêne G, Fleury H, Couzigou P, Bernard PH, French Multicenter Study Group.
    J Hepatol; 2002 May 06; 36(5):672-80. PubMed ID: 11983451
    [Abstract] [Full Text] [Related]

  • 16. Combination treatment of interferon alpha-2b and ribavirin in comparison to interferon monotherapy in treatment of chronic hepatitis C genotype 4 patients.
    el-Zayadi A, Selim O, Haddad S, Simmonds P, Hamdy H, Badran HM, Shawky S.
    Ital J Gastroenterol Hepatol; 1999 May 06; 31(6):472-5. PubMed ID: 10575565
    [Abstract] [Full Text] [Related]

  • 17. Sequential versus concomitant administration of ribavirin and interferon alfa-n3 in patients with chronic hepatitis C not responding to interferon alone: results of a randomized, controlled trial.
    Sostegni R, Ghisetti V, Pittaluga F, Marchiaro G, Rocca G, Borghesio E, Rizzetto M, Saracco G.
    Hepatology; 1998 Aug 06; 28(2):341-6. PubMed ID: 9695995
    [Abstract] [Full Text] [Related]

  • 18. Peginterferon alpha-2b plus ribavirin with or without amantadine [correction of amantidine] for the treatment of non-responders to standard interferon and ribavirin.
    Hasan F, Al-Khaldi J, Asker H, Al-Ajmi M, Owayed S, Varghese R, Siddique I, Al-Nakib B.
    Antivir Ther; 2004 Aug 06; 9(4):499-503. PubMed ID: 15456080
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 59.